Companies › MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
1 active drug program in 1 registered trial: 1 Phase 3; Neurology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Apomorphine D2-like dopamine receptor agonist | DRD2, DRD3, DRD4 | Phase 3 | Idiopathic Parkinson's Disease | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT02339064 | Apomorphine | Phase 3 | Idiopathic Parkinson's Disease | Neurology | Dec 2018 |
Prilenia Ambros Therapeutics Cerevance Green Valley (Shanghai) Pharmaceuticals CereMark Pharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.